• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Scaling across Series A to C

September 30, 2021 by David Barret Leave a Comment

Arthur Nobel
Contributor

Share on Twitter

Arthur Nobel is an entrepreneur turned investor, now working as principal at Knight Capital in Amsterdam, specializing in scaling companies. He started his career at Rocket Internet before holding various growth roles across Europe. Co-author of the book “Leaders of Growth,” he also hosts its related podcast.

The T2D3 (triple, triple, double, double, double) acronym has become a well-known goal in the startup scene for achieving unicorn status. Formulating the goal can be easy, but realizing such tremendous revenue growth is notoriously difficult.

A study from Dealroom shows that about 16% of the companies that raise a seed round manage to raise a Series B investment, and only about 7% of those that raise seed funding raise a Series C investment.

This statistic is partially explained by a lack of a good organizational framework for scaling companies across seed to Series C. There is a lot of great content on the startup phase (getting to product-market fit) and success stories (raising hundreds of millions of dollars and multibillion dollar exits), but there is little available on how founders can grow a company from $1 million to $25 million in annual revenues (broadly defined as the Series A, B and C stages).

Based on 47 interviews with industry experts including Sean Ellis, Mark Roberge, Bill Macaitis, Micha Breakstone and Brian Requarth, desk research and our own experience as founders and investors in Series A to C companies, we have derived three major insights about how to scale a company from the organizational perspective. Here’s our framework:

Scaling is a continuum with maturity stages

A fast-scaling company with revenue of $5 million revenue has different scaling needs compared to a fast-scaling startup with $15 million in revenue. The concept of “maturity stages” for scaling a company can be useful to address the different needs.

The most common “maturity stages” of scaling a company are:

  • Ad hoc.
  • Basic process.
  • Repeatable process.
  • Predictable process.
  • At scale.

Image Credits: Knight Capital

Typically, for a seed-stage company, everything is developed in a more or less ad-hoc manner. At the Series A stage, it’s more about developing repeatable processes. Series B and C are about predictability of outcomes. Beyond Series C, it’s about doing everything at scale.

Of course, this is a companywide view. As we argue below, this can be different for individual departments. For example, a company at a “repeatability” stage that generates inbound leads through digital marketing efforts and has an enterprise sales department will often have a much more mature marketing department compared to sales.

The takeaway is to initially figure out in which stage your company and departments are in and only do what is required for that stage.

The challenges to scaling

You scale a company, from an organizational perspective, by overcoming numerous challenges. We believe that these challenges can be largely categorized into five buckets:

  1. KPIs and data.
  2. People.
  3. Documentation and enablement.
  4. Processes.
  5. Tooling.

We believe it is best to approach these challenges on the departmental and subdepartmental levels to make it workable.

KPIs and data

Data-informed decision-making is particularly important in the T2D3 journey. It is important to realize that different KPIs are relevant at different stages. First, focus on the right metrics for your stage. An LTV:CAC metric (lifetime value to acquisition costs) is less relevant for a seed company than retention.

Source Link Scaling across Series A to C

David Barret
David Barret

Related posts:

  1. Kuwait starts to recycle massive tyre graveyard
  2. Cryptocurrencies selloff widens: Bitcoin down nearly 4%, ether 6%
  3. UK will be ‘hard-headed’ in defending interests, foreign minister says of security deal
  4. France cancels defence meeting with UK over submarine row, sources say

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • What Happens If Someone Actually Finds The Loch Ness Monster?
  • Golden Comet C/2025 K1 (ATLAS) Is A Chemical Rarity – And It Should Have Been Destroyed!
  • Bat Species Not Seen In 55 Years Rediscovered And Filmed For First Time – Just Look At Those Ears
  • At Last, We May Finally Have A Way To Tell Female Dinosaurs From Males
  • Giraffes In North American Zoos Have Been Hybridizing – And That’s A Problem
  • Watch: Cosmic Fireworks As Comet Fragment Traveling Over 80,000 Kilometers Per Hour Explodes In The Air
  • Why Don’t Birds Die When They Sit On 400,000-Volt Power Lines?
  • On November 13, 2026, Voyager Will Reach One Full Light-Day Away From Earth
  • Why Don’t We Ride Zebras?
  • Interstellar Object 3I/ATLAS Changed Color Again, And Shows Signs Of Non-Gravitational Acceleration
  • Record-Breaking Brightest Black Hole Flare Shines With The Light Of 10 Trillion Suns
  • The Feared Post-COVID “Disease Rebound” Of Rampaging Infections Never Really Happened
  • Why Do More People Believe Aliens Have Visited Earth?
  • This Antarctic Glacier Just Broke An Unwanted Record – Fastest Retreat In Modern History
  • New Portuguese Man O’ War Species Discovered After Warming Ocean Currents Push It North
  • Watch Orcas Use “Tonic Immobility” To Suck An Enormous Liver Out Of The World’s Deadliest Shark
  • Ancient Micronesians Hunted Sharks 1,800 Years Ago, And Now We Know Which Species
  • World’s First Plasma “Fireballs” Help Explain Supermassive Black Hole Mystery
  • Why Do We Eat Chicken, And Not Birds Like Seagull And Swan?
  • How To Find Fossils? These Bright Orange Organisms Love Growing On Exposed Dinosaur Bones
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version